Glaxo, Astellas duel for new place in anemia market; Novo Nordisk opens new U.S. HQ;

@FiercePharma: U.K. likely to pay for Avastin despite another NICE rejection. More | Follow @FiercePharma

@EricPFierce: Some popular drugs like Pradaxa, Prolia to be put through despised German price shredding formula. Story | Follow @EricPFierce

> Novo Nordisk ($NVO) opened a new U.S. headquarters in Plainsboro, N.J. Release

> Both GlaxoSmithKline ($GSK) and Japan's Astellas Pharma are working on pills for anemia to break into an $8 billion market targeted at injectable erythropoietin. Story

> Europe is looking to add environmental impact studies to evaluations of drugs. Report

> A watchdog group is asking regulators to look at the entire class of GLP-1 inhibitors for diabetes because of their link to a high number of cases of pancreatitis and pancreatic cancer. Report

> The South Korea-based biotech Celltrion has followed other drug developers in nixing late-stage development of a biosimilar version of Rituxan. Story

Medical Device News

@FierceMedDev: Hamburg: FDA is a bargain for taxpayers. Story | Follow @FierceMedDev

 @DamianFierce: LabCorp is slimming down and diversifying to stay profitable in a tough testing market. More | Follow @DamianFierce

> Intuitive Surgical's Q1 soars, despite da Vinci robot lawsuits. Article

> Covidien recalls ventilator batteries over failure risk. More

> Device company VC funding continues its plunge. Report

Biotech News

@FierceBiotech: Hear from top execs at Janssen talk about drug R&D, industry's drug pipeline efforts. More | Follow @FierceBiotech

@RyanMFierce: Biotech rattled as Q1 first-time VC deals plunge to 18-year low. News | Follow @RyanMFierce

> Pharma giants' oral EPO alternatives could cater to dopers. More

> Vertex skyrockets on positive Ph2 combo study in cystic fibrosis. Story

> Epizyme hits the biotech IPO queue with rapid R&D plan for cancer drugs. Report

And Finally... Cubist Pharmaceuticals ($CBST), which has said it is shooting for $2 billion in sales by 2017, reported its first quarter net income fell more than 80% after it paid $15 million to buy the rights to market an experimental antibiotic in more countries. Story

Suggested Articles

Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GSK's Zejula for the patient group.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.